Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes
Abstract Background Guidelines recommend combination therapy with glucagonlike peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) for cardiorenal risk reduction in people with type 2 diabetes (T2D); however, there is limited real-world evidence on the long...
Zapisane w:
| Główni autorzy: | , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BMC
2025-04-01
|
| Seria: | Cardiovascular Diabetology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1186/s12933-025-02737-1 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|